跳至主要内容
临床试验/NCT00921752
NCT00921752已完成不适用

C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)

AstraZeneca1 个研究点 分布在 1 个国家目标入组 1,500 人开始时间: 2009年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
1,500
试验地点
1
主要终点
Percent rate of patients achieving target LDL cholesterol goals

研究概览

简要总结

To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients at high cardiovascular risk according to Framingham or SCORE rates

排除标准

  • Not eligible for lipid or statin therapy
  • Intolerance to therapy
  • Patients at low or intermediate CV risk

结局指标

主要结局

Percent rate of patients achieving target LDL cholesterol goals

时间窗: On each of the 3 visits performed during the study

Percent rate of patients achieving 50% or more reduction in LDL-cholesterol

时间窗: On each of the 3 visits performed during the study

次要结局

  • Percent rate of patients achieving target secondary (total Ch, triglycerides, HDL Ch) goals(On each of the 3 visits performed during the study)
  • Percent rate of compliance among patients in the study(On each of the 3 visits performed during the study)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验